Software As A Medical Device (SaMD) For Cardiology Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Software As A Medical Device (SaMD) For Cardiology Market Trends and Insights

Regulatory Push Is Creating a First-Mover Reimbursement Moat

Regulatory momentum is giving the Software as a Medical Device (SaMD) for Cardiology market a faster route from approval to revenue. FDA cardiology AI and ML clearances rose to 92 in 2025 from 62 in 2024, widening the pool of tools ready for deployment. Eight of the 2025 clearances included a Predetermined Change Control Plan, which allows post-market algorithm updates within an approved framework. This gives early-cleared vendors an advantage in improving performance with live clinical data while staying within the approved regulatory pathway.

Reimbursement Expansion Is the Demand Unlock the Market Was Waiting For

Payment expansion is removing one of the last major barriers in the Software as a Medical Device (SaMD) for Cardiology market. CMS made CPT code 75577 effective on January 1, 2026, with a USD 950.50 hospital outpatient payment for AI-enabled coronary plaque analysis from CCTA. CMS also created code G0680 for AI-based coronary artery calcium and aortic valve calcium analysis on chest CT, while trade reporting showed a USD 128.90 national Medicare payment rate for AI-enabled ECG analysis under CPT codes 0764T and 0765T. Predictable payment is helping hospitals and outpatient sites link software adoption to a defined reimbursement pathway.^{[1]Centers for Medicare & Medicaid Services, “Billing and Coding: Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QCT)/Coronary Plaque Analysis (AI-CPA) (A59716),” CMS, cms.gov}

The Arrhythmia Detection Burden Is Larger Than Reported Incidence Suggests

The scale of undiagnosed rhythm disorders is also pulling the Software as a Medical Device (SaMD) for Cardiology market forward. iRhythm stated that 27 million people in the United States are at risk for undiagnosed arrhythmias each year, keeping screening demand well above the diagnosed patient base. A 2025 Nature Medicine study on 14,606 ambulatory ECG recordings found that DeepRhythmAI achieved 98.6% sensitivity for critical arrhythmias, compared with 80.3% for certified human technicians. iRhythm's 2026 revenue guidance of USD 870-880 million further showed that large-scale rhythm monitoring platforms are converting clinical demand into commercial scale.^{[2]A. Hussain et al., “Is the FDA Regulation of Cardiology AI Devices Supporting Innovation?,” BMJ Heart, heart.bmj.com}

Remote Cardiac Monitoring Is Shifting Clinical Gravity from Hospitals to the Home

Remote care is shifting part of the Software as a Medical Device (SaMD) for Cardiology market away from hospital settings and toward continuous follow-up. Home Healthcare and Remote Monitoring Providers are projected to expand at a 19.78% CAGR from 2026 to 2031, making them the fastest-growing end-user group in the draft. This growth reflects rising demand for software that can interpret ECG data, stratify risk, and route patients into follow-up without repeated in-person visits. As cardiac follow-up moves into homes and outpatient settings, vendors that connect data capture, interpretation, and care coordination are in a stronger position.

Thin Clinical Evidence Is the Structural Vulnerability Beneath the Clearance Headline

Evidence quality remains a key constraint in the Software as a Medical Device (SaMD) for Cardiology market. A 2026 review of 277 FDA-cleared cardiology AI and ML devices found that bench studies accounted for 69.3% of validation studies, while prospective multicenter clinical trials accounted for only 3.2%. The same review reported a high risk of predicate creep in 52.2% of cleared cardiology AI devices, raising concerns over how far newer claims had moved from the original validated use case. CMS had already applied strict procedural criteria in LCD L39881 for AI-enabled coronary plaque analysis, showing that reimbursement can tighten as evidence standards rise.^{[3]L.S. Johnson, P. Zadrozniak, G. Jasina et al., “Artificial Intelligence for Direct-to-Physician Reporting of Ambulatory Electrocardiography,” Nature Medicine, doi.org} Vendors with broader multi-site validation and cleaner clinical datasets are better positioned to defend coverage and pricing as scrutiny increases.

Cybersecurity Incidents Are Reshaping the Risk Calculus for Payers and Providers

Cybersecurity and data governance are slowing adoption in the Software as a Medical Device (SaMD) for Cardiology market, even when clinical need is clear. These platforms handle protected health information across cloud, edge, and hospital systems, making privacy reviews part of the full operating environment. Providers are spending more time on security due diligence, contract terms, data flow mapping, and third-party risk reviews before deployment, which extends enterprise sales cycles and raises implementation costs. Vendors that demonstrate strong governance, interoperable architecture, and clear accountability for incident response are better positioned to win large health system contracts.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Diagnostic Tools Define the Market's Foundation

Diagnostic SaMD held 38.65% of the Software as a Medical Device (SaMD) for Cardiology market share in 2025, making it the foundation of current revenue. Its leadership reflected the smooth integration of diagnostic outputs into established cardiology workflows, especially in imaging-led hospital settings. In 2025, coronary CT tools alone accounted for 9 plaque quantification clearances, 7 calcium scoring clearances, and 3 FFR-derived clearances in the United States. This concentration kept diagnostic software closely aligned with routine ordering patterns, reimbursement use, and physician acceptance.

Monitoring SaMD is projected to grow at a CAGR of 18.93% from 2026 to 2031, making it the fastest-growing product type in the Software as a Medical Device (SaMD) for Cardiology market size. Growth is moving beyond simple ambulatory ECG patches toward software that combines ECG, impedance, and activity data in a single monitoring stream. Clinical decision support tools are also gaining traction as payment models begin to reward specific outputs, such as AI-enabled ECG interpretation, rather than only raw signal review. Therapeutic software remains the smallest product group as regulators continue to take a cautious approach to closed-loop or therapy-adjusting cardiac applications.

By Clinical Application: Heart Failure Management Is Re-Shaping the Market's Growth Profile

Arrhythmia detection accounted for 35.23% of the clinical application mix in 2025, keeping it at the center of current spending. The segment benefited from a large undiagnosed population, a longer history of cleared rhythm tools, and clearer reimbursement visibility than many newer cardiac applications. Hospitals and ambulatory rhythm programs already understood how to use ECG-based software, which reduced adoption friction. This installed base also allowed arrhythmia tools to become the first software layer within broader digital cardiology strategies.

Heart failure management is forecast to grow at a CAGR of 19.67% through 2031, giving it the fastest expansion profile within the Software as a Medical Device (SaMD) for Cardiology market. Remote hemodynamic monitoring, AI-driven risk stratification, and the ongoing need to reduce readmissions across health systems support this growth. Coronary artery disease assessment is also advancing after reimbursement support for AI-enabled plaque analysis, although the patent dispute between HeartFlow and Cleerly showed intensifying competition in this sub-segment. Structural heart disease assessment and cardiac imaging analysis continue to benefit from automation that reduces manual review time and supports standardized interpretation.

By Deployment Model: Cloud Dominates, but Hybrid Architecture Is Where the Enterprise Deals Are

Cloud-based deployment held 61.34% of the model mix in 2025, making it the operating default for much of the Software as a Medical Device (SaMD) for Cardiology market. Providers favored cloud delivery because it supported subscription pricing, centralized updates, and scalable computing for imaging and ECG review. It also suited platforms that required continuous retraining, feature refreshes, and broader data aggregation after launch. For vendors, cloud delivery shortened rollout timelines across multi-site health systems that preferred one administrative layer over multiple local installations.

Hybrid deployment is projected to grow at a CAGR of 18.35% from 2026 to 2031, making it the fastest-growing model in the Software as a Medical Device (SaMD) for Cardiology market. Health systems increasingly want local edge processing for time-sensitive arrhythmia alerts and cloud processing for higher-volume imaging analytics. Hybrid architecture gives them tighter latency control without sacrificing enterprise scale, centralized management, or easier software updates. On-premise deployment still retains a role in parts of APAC and the Middle East, where data residency rules or public hospital IT policies limit cloud use.

By End User: Hospitals Lead, but the Growth Opportunity Lies Beyond the Clinic

Hospitals and health systems held 42.88% of end-user demand in 2025, keeping them as the largest buyers in the Software as a Medical Device (SaMD) for Cardiology market. Their leadership was supported by the fact that most decision support tools still depended on enterprise EHR integration, imaging connectivity, and formal clinical governance. Large health systems also justified deployment spending more easily when software supported cardiology, radiology, emergency, and outpatient service lines. This gave an advantage to vendors that supported procurement, security review, clinician training, and multi-site implementation at system scale.

Home healthcare and remote monitoring providers are forecast to grow at a CAGR of 19.78% through 2031, making them the fastest-growing end-user group. Consumer-connected ECG tools and software-led review workflows are creating care coordination models that reach patients between visits and after discharge. Cardiology clinics remain a structurally underserved channel, especially for AI-assisted ECG interpretation and remote monitoring review. Ambulatory care centers and diagnostic imaging centers are also responding quickly to reimbursable CCTA plaque analysis workflows that align with outpatient throughput expectations.

Geography Analysis

North America held 40.56% of the Software as a Medical Device (SaMD) for Cardiology market share in 2025, maintaining its global lead. The United States moved faster than other countries on reimbursement, with separate Medicare payment pathways in place for AI-enabled coronary plaque analysis, ECG analysis, and calcium analysis. This payment clarity supported commercial scale for pure-play vendors and imaging incumbents. The region also benefited from a large installed hospital base, while Canada and Mexico advanced despite reimbursement frameworks trailing the United States.

Asia-Pacific is projected to grow at a 17.56% CAGR from 2026 to 2031, making it the fastest-growing regional bloc in the Software as a Medical Device (SaMD) for Cardiology market. Growth is being driven by cardiovascular disease burden, national digitization efforts, and stronger regulatory alignment across major countries. Japan and South Korea are advancing with clearer product approvals, while China is attracting investment that links procedural hardware with software-enabled cardiac workflows. India and Southeast Asia remain earlier in adoption, where public health digitization programs are shaping near-term demand more than private reimbursement.

Europe held the third-largest regional share in 2025, with Germany, the United Kingdom, and France forming the main demand base. A stricter compliance environment is raising entry and product maintenance requirements while favoring vendors with stronger regulatory depth. The Middle East and Africa are still earlier in adoption, but Gulf markets are using FDA and CE pathways as reference points for local registration and early procurement. South America is gradually building its position as Brazil and Argentina work on reimbursement frameworks for AI diagnostics.